(CercleFinance.com) – Industrial biotech Amoéba formalized on Monday a review of its growth strategy following the recent implementation of new governance, an announcement which caused its stock to jump on the Paris Stock Exchange.
The company, which specializes in the treatment of microbiological risks, explains that it wants to shorten the time needed to generate a positive operating cash flow.
It therefore plans to focus on product development and markets offering the best prospects for profitability and faster commercialization.
By favoring high-margin activities and not high-volume activities, the company plans to meet planned production in the short and medium term, by extending production capacities at Chassieu, the company’s current headquarters.
The construction of the factory planned in Cavaillon, the financing of which has still not been finalized, would thus be put on hold until the turnover generated by sales produced from Chassieu, near Lyon, provides cash -sufficient operational flow.
These announcements were welcomed Monday morning on the Paris Stock Exchange, where the stock soared by almost 17%.
As a reminder, the group has received marketing authorization in the United States for a biocontrol agent for the treatment of plants in agriculture, as well as for a biological biocide that can be used in closed cooling systems.
Last month, Amoéba appointed Benoit Villers, the former commercial general manager of the Barry Callebaut group and founder of Nice & Green, the company’s largest shareholder with a 29.4% stake, to the position of chairman of the board of directors.
The board of directors also appointed Jean-François Doucet, previously deputy general manager, to the position of general manager of the company.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on AMOEBA in real time: